title: Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet.
abstract: Combining pharmacological treatments and life style interventions is necessary for effective therapy of major diseases associated with obesity, which are clustered in the metabolic syndrome. Acting via multiple mechanisms, combination treatments may reduce dose requirements and, therefore, lower the risk of adverse side effects, which are usually associated with long-term pharmacological interventions. Our previous study in mice fed high-fat diet indicated additivity in preservation of insulin sensitivity and in amelioration of major metabolic syndrome phenotypes by the combination treatment using n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) and rosiglitazone, i.e. an anti-diabetic drug of the thiazolidinedione (TZD) family. We investigated here whether pioglitazone, a TZD-drug in clinical use, could elicit the additive beneficial effects when combined with n-3 LC-PUFA. Adult male mice (C57BL/6N) were fed an obesogenic corn oil-based high-fat diet (cHF) for 8 weeks, or randomly assigned to various dietary treatments (i) cHF+F, cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids; (ii) cHF+ROSI, cHF with 10 mg rosiglitazone/kg diet; (iii) cHF+F+ROSI; (iv) cHF+PIO, cHF with 50 mg pioglitazone/kg diet; and (v) cHF+F+PIO, or chow-fed. Plasma concentrations of 163 metabolites were evaluated using a targeted metabolomics approach. Both TZDs preserved glucose homeostasis and normal plasma lipid levels while inducing adiponectin, with pioglitazone showing better effectiveness. The beneficial effects of TZDs were further augmented by the combination treatments. cHF+F+ROSI but not cHF+F+PIO counteracted development of obesity, in correlation with inducibility of fatty acid β-oxidation, as revealed by the metabolomic analysis. By contrast, only cHF+F+PIO eliminated hepatic steatosis and this treatment also reversed insulin resistance in dietary obese mice. Our results reveal differential effects of rosiglitazone and pioglitazone, unmasked in the combination treatment with n-3 LC-PUFA, and support the notion that n-3 LC-PUFA could be used as add-on treatment to TZDs in order to improve diabetic patient's therapy.
authors.affiliation: Department of Adipose Tissue Biology, Institute of Physiology Academy of Sciences of the Czech Republic v.v.i., Prague, Czech Republic.
authors.forename: Vladimir
authors.initials: V
authors.lastname: Kus
authors.forename: Pavel
authors.initials: P
authors.lastname: Flachs
authors.forename: Ondrej
authors.initials: O
authors.lastname: Kuda
authors.forename: Kristina
authors.initials: K
authors.lastname: Bardova
authors.forename: Petra
authors.initials: P
authors.lastname: Janovska
authors.forename: Michaela
authors.initials: M
authors.lastname: Svobodova
authors.forename: Zuzana Macek
authors.initials: ZM
authors.lastname: Jilkova
authors.forename: Martin
authors.initials: M
authors.lastname: Rossmeisl
authors.forename: Rui
authors.initials: R
authors.lastname: Wang-Sattler
authors.forename: Zhonghao
authors.initials: Z
authors.lastname: Yu
authors.forename: Thomas
authors.initials: T
authors.lastname: Illig
authors.forename: Jan
authors.initials: J
authors.lastname: Kopecky
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D004041:Dietary Fats / Q000008:administration & dosage*; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D006706:Homeostasis; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008055:Lipids / Q000097:blood; D008297:Male; D055432:Metabolomics; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000517:prevention & control; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage*
chemical_list: D001786:Blood Glucose; D004041:Dietary Fats; D015525:Fatty Acids, Omega-3; D007004:Hypoglycemic Agents; D008055:Lipids; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077205:Pioglitazone
references.citation: Diabetologia. 2007 Mar;50(3):654-65
references.pmid: 17245590
references.citation: Diabetes. 1999 Jan;48(1):134-40
references.pmid: 9892234
references.citation: Int J Biochem Cell Biol. 2011 Aug;43(8):1071-4
references.pmid: 21558015
references.citation: Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1009-17
references.pmid: 18765680
references.citation: J Biol Chem. 2010 Nov 19;285(47):36361-8
references.pmid: 20843793
references.citation: N Engl J Med. 2010 Nov 18;363(21):2015-26
references.pmid: 20929341
references.citation: Lancet. 2010 Aug 14;376(9740):540-50
references.pmid: 20638121
references.citation: J Am Diet Assoc. 2005 Mar;105(3):428-40
references.pmid: 15746832
references.citation: Diabetes Metab Res Rev. 2010 May;26(4):297-305
references.pmid: 20503262
references.citation: Int J Obes (Lond). 2012 Feb;36(2):262-72
references.pmid: 21540832
references.citation: Diabetes. 2010 Nov;59(11):2737-46
references.pmid: 20693347
references.citation: Metabolism. 1996 Dec;45(12):1539-46
references.pmid: 8969289
references.citation: Diabetes Care. 2005 Jul;28(7):1547-54
references.pmid: 15983299
references.citation: Obesity (Silver Spring). 2010 Sep;18(9):1695-700
references.pmid: 20111019
references.citation: PLoS One. 2009;4(4):e5258
references.pmid: 19390588
references.citation: Diabetologia. 2004 Dec;47(12):2215-25
references.pmid: 15662559
references.citation: Diabetes Care. 2007 Oct;30(10):2458-64
references.pmid: 17595355
references.citation: Nat Genet. 2010 Feb;42(2):137-41
references.pmid: 20037589
references.citation: J Physiol Pharmacol. 2009 Dec;60(4):135-40
references.pmid: 20065507
references.citation: Am J Physiol Endocrinol Metab. 2003 Aug;285(2):E354-62
references.pmid: 12700163
references.citation: Life Sci. 2010 Sep 25;87(13-14):405-10
references.pmid: 20723549
references.citation: Diabetologia. 2007 Jun;50(6):1127-39
references.pmid: 17393135
references.citation: Diabetologia. 2006 Sep;49(9):2109-19
references.pmid: 16783472
references.citation: Diabetologia. 2008 Jan;51(1):8-11
references.pmid: 18026926
references.citation: Biochim Biophys Acta. 2005 May 30;1740(2):266-86
references.pmid: 15949694
references.citation: Lipids. 2004 Dec;39(12):1177-85
references.pmid: 15736913
references.citation: Diabetes Obes Metab. 2010 Sep;12(9):806-14
references.pmid: 20649633
references.citation: Crit Rev Clin Lab Sci. 2004;41(1):41-78
references.pmid: 15077723
references.citation: Prog Lipid Res. 2009 Jan;48(1):44-51
references.pmid: 19032965
references.citation: J Clin Invest. 2004 Nov;114(9):1281-9
references.pmid: 15520860
references.citation: Diabetologia. 2009 May;52(5):941-51
references.pmid: 19277604
references.citation: Curr Med Res Opin. 2010 Apr;26(4):907-15
references.pmid: 20156032
references.citation: Mol Cell. 2011 Jan 21;41(2):139-49
references.pmid: 21255725
references.citation: Cell Metab. 2008 Jan;7(1):45-56
references.pmid: 18177724
references.citation: J Biol Chem. 2006 Feb 3;281(5):2654-60
references.pmid: 16326714
references.citation: BMJ. 2007 Feb 10;334(7588):299
references.pmid: 17237299
references.citation: J Hum Nutr Diet. 2004 Oct;17(5):449-59
references.pmid: 15357699
references.citation: Diabetologia. 2006 Feb;49(2):394-7
references.pmid: 16397791
references.citation: BMJ. 2011 Mar 17;342:d1309
references.pmid: 21415101
references.citation: PLoS One. 2010 Jul 12;5(7):e11519
references.pmid: 20634953
references.citation: J Clin Invest. 2001 Oct;108(7):1001-13
references.pmid: 11581301
references.citation: Ann N Y Acad Sci. 1993 Jun 14;683:272-8
references.pmid: 8251021
references.citation: Physiol Res. 2006;55(1):63-72
references.pmid: 15857162
references.citation: Expert Opin Pharmacother. 2011 Jun;12(9):1429-38
references.pmid: 21426238
references.citation: Diabetologia. 2005 Nov;48(11):2365-75
references.pmid: 16205884
references.citation: Diabetes. 1991 May;40(5):583-9
references.pmid: 2022303
references.citation: Science. 1987 Aug 21;237(4817):885-8
references.pmid: 3303333
references.citation: Am J Cardiol. 2007 Feb 19;99(4A):27B-40B
references.pmid: 17307056
references.citation: Pharmacol Ther. 2005 Jan;105(1):7-21
references.pmid: 15626453
references.citation: J Pharm Biomed Anal. 2009 May 1;49(4):976-82
references.pmid: 19249171
references.citation: Diabetologia. 2011 Oct;54(10):2626-38
references.pmid: 21779874
references.citation: PLoS One. 2007 Feb 14;2(2):e218
references.pmid: 17299598
references.citation: Diabetes Care. 2011 Apr;34(4):916-22
references.pmid: 21447663
references.citation: Cell. 2010 Sep 3;142(5):687-98
references.pmid: 20813258
references.citation: Diabetes. 1997 Apr;46(4):701-10
references.pmid: 9075814
references.citation: Diabetes. 2006 Apr;55(4):924-8
references.pmid: 16567512
references.citation: BMC Genomics. 2009 Mar 16;10:110
references.pmid: 19284886
references.citation: Am J Physiol Endocrinol Metab. 2009 Feb;296(2):E384-93
references.pmid: 19066319
references.citation: Diabetes Obes Metab. 2011 Apr;13(4):313-25
references.pmid: 21205114
references.citation: Nature. 2000 Apr 6;404(6778):635-43
references.pmid: 10766250